Skip to main content

Treatment for Mild Chronic Hypertension during Pregnancy.

Publication ,  Journal Article
Tita, AT; Szychowski, JM; Boggess, K; Dugoff, L; Sibai, B; Lawrence, K; Hughes, BL; Bell, J; Aagaard, K; Edwards, RK; Gibson, K; Haas, DM ...
Published in: N Engl J Med
May 12, 2022

BACKGROUND: The benefits and safety of the treatment of mild chronic hypertension (blood pressure, <160/100 mm Hg) during pregnancy are uncertain. Data are needed on whether a strategy of targeting a blood pressure of less than 140/90 mm Hg reduces the incidence of adverse pregnancy outcomes without compromising fetal growth. METHODS: In this open-label, multicenter, randomized trial, we assigned pregnant women with mild chronic hypertension and singleton fetuses at a gestational age of less than 23 weeks to receive antihypertensive medications recommended for use in pregnancy (active-treatment group) or to receive no such treatment unless severe hypertension (systolic pressure, ≥160 mm Hg; or diastolic pressure, ≥105 mm Hg) developed (control group). The primary outcome was a composite of preeclampsia with severe features, medically indicated preterm birth at less than 35 weeks' gestation, placental abruption, or fetal or neonatal death. The safety outcome was small-for-gestational-age birth weight below the 10th percentile for gestational age. Secondary outcomes included composites of serious neonatal or maternal complications, preeclampsia, and preterm birth. RESULTS: A total of 2408 women were enrolled in the trial. The incidence of a primary-outcome event was lower in the active-treatment group than in the control group (30.2% vs. 37.0%), for an adjusted risk ratio of 0.82 (95% confidence interval [CI], 0.74 to 0.92; P<0.001). The percentage of small-for-gestational-age birth weights below the 10th percentile was 11.2% in the active-treatment group and 10.4% in the control group (adjusted risk ratio, 1.04; 95% CI, 0.82 to 1.31; P = 0.76). The incidence of serious maternal complications was 2.1% and 2.8%, respectively (risk ratio, 0.75; 95% CI, 0.45 to 1.26), and the incidence of severe neonatal complications was 2.0% and 2.6% (risk ratio, 0.77; 95% CI, 0.45 to 1.30). The incidence of any preeclampsia in the two groups was 24.4% and 31.1%, respectively (risk ratio, 0.79; 95% CI, 0.69 to 0.89), and the incidence of preterm birth was 27.5% and 31.4% (risk ratio, 0.87; 95% CI, 0.77 to 0.99). CONCLUSIONS: In pregnant women with mild chronic hypertension, a strategy of targeting a blood pressure of less than 140/90 mm Hg was associated with better pregnancy outcomes than a strategy of reserving treatment only for severe hypertension, with no increase in the risk of small-for-gestational-age birth weight. (Funded by the National Heart, Lung, and Blood Institute; CHAP ClinicalTrials.gov number, NCT02299414.).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

May 12, 2022

Volume

386

Issue

19

Start / End Page

1781 / 1792

Location

United States

Related Subject Headings

  • Premature Birth
  • Pregnancy Outcome
  • Pregnancy
  • Pre-Eclampsia
  • Infant, Newborn
  • Hypertension, Pregnancy-Induced
  • Hypertension
  • Humans
  • General & Internal Medicine
  • Fetal Growth Retardation
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tita, A. T., Szychowski, J. M., Boggess, K., Dugoff, L., Sibai, B., Lawrence, K., … Chronic Hypertension and Pregnancy (CHAP) Trial Consortium. (2022). Treatment for Mild Chronic Hypertension during Pregnancy. N Engl J Med, 386(19), 1781–1792. https://doi.org/10.1056/NEJMoa2201295
Tita, Alan T., Jeff M. Szychowski, Kim Boggess, Lorraine Dugoff, Baha Sibai, Kirsten Lawrence, Brenna L. Hughes, et al. “Treatment for Mild Chronic Hypertension during Pregnancy.N Engl J Med 386, no. 19 (May 12, 2022): 1781–92. https://doi.org/10.1056/NEJMoa2201295.
Tita AT, Szychowski JM, Boggess K, Dugoff L, Sibai B, Lawrence K, et al. Treatment for Mild Chronic Hypertension during Pregnancy. N Engl J Med. 2022 May 12;386(19):1781–92.
Tita, Alan T., et al. “Treatment for Mild Chronic Hypertension during Pregnancy.N Engl J Med, vol. 386, no. 19, May 2022, pp. 1781–92. Pubmed, doi:10.1056/NEJMoa2201295.
Tita AT, Szychowski JM, Boggess K, Dugoff L, Sibai B, Lawrence K, Hughes BL, Bell J, Aagaard K, Edwards RK, Gibson K, Haas DM, Plante L, Metz T, Casey B, Esplin S, Longo S, Hoffman M, Saade GR, Hoppe KK, Foroutan J, Tuuli M, Owens MY, Simhan HN, Frey H, Rosen T, Palatnik A, Baker S, August P, Reddy UM, Kinzler W, Su E, Krishna I, Nguyen N, Norton ME, Skupski D, El-Sayed YY, Ogunyemi D, Galis ZS, Harper L, Ambalavanan N, Geller NL, Oparil S, Cutter GR, Andrews WW, Chronic Hypertension and Pregnancy (CHAP) Trial Consortium. Treatment for Mild Chronic Hypertension during Pregnancy. N Engl J Med. 2022 May 12;386(19):1781–1792.

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

May 12, 2022

Volume

386

Issue

19

Start / End Page

1781 / 1792

Location

United States

Related Subject Headings

  • Premature Birth
  • Pregnancy Outcome
  • Pregnancy
  • Pre-Eclampsia
  • Infant, Newborn
  • Hypertension, Pregnancy-Induced
  • Hypertension
  • Humans
  • General & Internal Medicine
  • Fetal Growth Retardation